GCCL Co., Ltd. (GCCL), a data-driven clinical trial services provider, and Medicover Integrated Clinical Services (MICS), part of Medicover, an international healthcare and diagnostic services company, have signed a Memorandum of Understanding (MOU) to collaborate on multinational clinical trial services.

Through this MOU, the two companies aim to establish a collaborative framework covering Europe, the United States, and the Asia-Pacific (APAC) region. By leveraging their respective experience in clinical trial operations and client communications across key regions, the partnership seeks to enhance cross-regional communication efficiency and improve operational stability in global clinical trial projects.

Key areas of collaboration under the MOU include clinical trial operations and sample analysis collaboration across regions; project management support and coordinated client communication by region; joint marketing collaboration; joint client development and market expansion; and the enhancement of service competitiveness through test item alignment and improved analytical efficiency.

By combining MICS's extensive experience and network in Europe and the U.S. with GCCL's specialized analytical capabilities and project management expertise in the APAC region, the two companies expect to offer a more seamlessly connected and optimized environment for multinational clinical trial operations and analysis.

"This agreement represents an important opportunity to effectively combine the expertise and customer bases of both organizations and further strengthen the global clinical trial ecosystem," said Łukasz Hubisz, General Manager of MICS. "Through our collaboration with GCCL, we aim to strengthen communication with clients in Asia and support the smoother execution of global clinical trial projects."

Kwan Goo Cho, CEO of GCCL, added, "This partnership marks an important first step in reinforcing clinical collaboration between Europe and Asia. Through our strategic cooperation with MICS, we aim to set new standards for global clinical trial execution and deliver meaningful analytical outcomes for our clients."